Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company’s drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics – a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. To learn more, visit www.thirdarcbio.com.
| Website | https://thirdarcbio.com/ |
| Revenue | $5.6 million |
| Employees | 42 (27 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Clinical Trials, Biotechnology, Biotechnology Research, Immunotherapy, Antibody Engineering, T Cell Therapy, Drug Development, Biologics, Therapeutics, Precision Medicine, Cancer Treatment, Pharmaceutical, Biopharma, Immunomodulation, Targeted Therapy, Cell Signaling, Protein Engineering |
| Competitors | Amgen, Novozymes, Codexis, Inc., Geno, Zymergen, Inc., Arzeda, Telesis Bio, Synthace, Biosyntia, BIOMILLENIA +39 more (view full list) |
Looking for a particular Third Arc Bio employee's phone or email?
The Third Arc Bio annual revenue was $5.6 million in 2026.
Sanjaya Singh is the Chief Scientific Officer and Founder of Third Arc Bio.
27 people are employed at Third Arc Bio.
Third Arc Bio is based in Philadelphia, Pennsylvania.